$GILD News Selling in growth-stock leaders continues

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2013 at 9:59 PM

$GILD News

Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune 4:47 p.m. July 25, 2013 - Russ Britt
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Gilead profit up 8.6% on sales growth of HIV drugs 3:37 p.m. July 25, 2013 - MarketWatch.com
Gilead profit rises, sales beat forecast 3:19 p.m. July 25, 2013 - Russ Britt

'Mad Money' Lightning Round: Don't Sell Sirius 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:17 p.m. Nov. 8, 2013 - TheStreet.com
Gilead Vs. Challengers In The Hepatitis C Race 7:00 a.m. Nov. 7, 2013 - Seeking Alpha
Roche Pacing the Field in the Biotech Race 6:00 a.m. Nov. 6, 2013 - TheStreet.com
U.S. Launch of Actelion's Opsumit - Analyst Blog 4:30 p.m. Nov. 5, 2013 - Zacks.com
Ligand Pharmaceuticals On Pace For Annual Profit 4:25 p.m. Nov. 5, 2013 - Investors Business Daily
Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read 11:25 a.m. Nov. 5, 2013 - Wall St. Cheat Sheet
Gilead Sciences Inc Continues With Buy Recommendation 9:00 a.m. Nov. 5, 2013 - TheStreet.com
UBS Adds Six Top Alpha Preference List Stocks to Buy for 2014 7:34 a.m. Nov. 5, 2013 - 247WallSt.com
Stock Splits Rekindle a Polarizing Debate 8:44 p.m. Nov. 4, 2013 - WSJ.com
Top-Performing Mutual Funds Like Facebook 5:01 p.m. Nov. 4, 2013 - Investors Business Daily
Bristol-Myers Seeks Japanese Approval - Analyst Blog 2:30 p.m. Nov. 4, 2013 - Zacks.com
Protect Your Investments Against a Bubble, Know What Makes a Bubble 10:28 a.m. Nov. 4, 2013 - TheStreet.com
Benzinga's Top #PreMarket Losers 7:37 a.m. Nov. 4, 2013 - benzinga.com
Invest In Gilead Sciences For Long-Term Hepatitis C Franchise 2:13 a.m. Nov. 4, 2013 - Seeking Alpha
Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV 4:15 p.m. Nov. 2, 2013 - benzinga.com
Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients 4:12 p.m. Nov. 2, 2013 - benzinga.com
Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex 6:40 a.m. Nov. 2, 2013 - 247WallSt.com
Jim Cramer's 6 Stocks in 60 Seconds: VRTX GTLS YELP AVD Q GRPN (Update 1) 5:20 p.m. Nov. 1, 2013 - TheStreet.com
Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day 4:15 a.m. Oct. 31, 2013 - Zacks.com

S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver 9:31 a.m. Oct. 29, 2013 - PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 9:00 a.m. Oct. 28, 2013 - PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection 4:43 p.m. Oct. 25, 2013 - BusinessWire
Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013 5:00 p.m. Oct. 22, 2013 - BusinessWire
Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics 8:00 a.m. Oct. 22, 2013 - PR Newswire
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer 9:05 a.m. Oct. 21, 2013 - PR Newswire
Insider Trading Tips for Google, Rite Aid, American Express, Advanced Micro Devices, J.C. Penney, and Ariad Pharmaceuticals 8:55 a.m. Oct. 21, 2013 - PR Newswire
Gilead's Single Tablet HIV Regimen Stribild(R) Demonstrates Durable Viral Suppression Through Three Years of Therapy 3:10 a.m. Oct. 16, 2013 - BusinessWire
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection 7:00 a.m. Oct. 15, 2013 - Thomson Reuters ONE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Fosun Pharma Hits the Buyback Button: What's Next?

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

XiamenAir Takes Off with Fujian-London Link

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

MERACH Unveils W60 Plus: A Game Changer for Home Fitness

MERACH's Ambitious Leap into European Markets Walking is one of life's simple pleasures, but it's not always convenient in our work-from-home driven world. That's where MERACH's UltraWalk W60 Plus comes in, dropping anchor in Europe like a brand new ship with all the bells and whistles. What makes this walking pad different, you ask? It's designed to become a natural...

Ice-Rock Avalanches: Future Risks and Urgent Lessons

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

ATTACK SHARK Partners with Cloud9 League Team

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Creality Rolls Out K3, SPARKX i8 at IFA 2026

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

China's Manufacturing: Squeeze or Opportunity?

Analyzing China's Impact on Global Markets Think of China's manufacturing clout and you're likely to picture booming factories, relentless steel, and smoke-churning industries reshaping the global chessboard. But here's the kicker: are they swallowing up room for others, or paving the way for their growth? It’s this debate that took the spotlight at the Asia-Pacific...

DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...